Israel approves fourth COVID-19 vaccine jab for elderly, medical staff
Category: #healthcare  By Mateen Dalal  Date: 2022-01-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Israel approves fourth COVID-19 vaccine jab for elderly, medical staff

Israel PM Naftali Bennett recently announced that Israelis aged 60 and above, and medical personnel, can receive a fourth shot of the coronavirus vaccination as the region witnesses a spike in COVID-19 cases.

The Pandemic Response Committee recommended new booster shots to be administered, however Health Ministry Director-General Nachman Ash decided to delay the next jab. He authorized the vaccine for immunocompromised patients and inhabitants of retirement homes last week, but not to the elderly.

Bennett stated that the decision came after professional considerations and consultation of the Health Ministry with specialists. In the coming days, Israel is likely to see almost 50,000 new cases per day, which would be five times the number seen in prior waves, he warned.

It is to be noted that individuals above the age of 60, and medical staff, must have received the third immunization at least six months before receiving the current booster.

Prof. Eran Segal of the Weizmann Institute of Science indicated that between two and four million Israelis, or more than 40% of the population, could be infected with the Omicron variant over the next three weeks.

Recently, Israel reported 5,500 new virus carriers last Friday, indicating a three-times increase in the number found previously, with over 4% of the tests returning a positive result. An additional 4,200 instances were discovered the following day, with about 100,000 tests processed, similar to the previous weekdays.

While over 40% of novel virus carriers recognized in the last week had got a booster, the majority of patients in critical condition were either not vaccinated at all or had been vaccinated more than six months earlier, with 21 of them receiving a booster as well, all of whom were over 60.

The Health Ministry said that it signed a contract to purchase the antiviral medication Molnupiravir, meant to be given to coronavirus patients who have mild or moderate symptoms. The US Food and Drug Administration granted emergency-use approval to the treatment, which reduced hospitalizations and fatalities by 30%.

Source Credit-

https://www.jpost.com/health-and-wellness/coronavirus/article-691344

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Ellipsis Health, Augmedix to offer automated mental health patient screenings
Ellipsis Health, Augmedix to offer automated mental health patient screenings
By Mateen Dalal

AI vocal biomarker technology provider Ellipsis Health has reportedly disclosed a strategic partners...

Enevate, NantG Power partner to develop next-gen ultra-high-performance battery
Enevate, NantG Power partner to develop next-gen ultra-high-performance battery
By Mateen Dalal

A strategic agreement to produce next-generation battery was announced by Enevate and NantG Power, t...

TPG in plans to invest $336M in Denodo for accelerating growth
TPG in plans to invest $336M in Denodo for accelerating growth
By Mateen Dalal

Denodo, a leading data management company, and TPG, a global alternative asset management ...